Kala Bio (KALA) Raw Materials (2018 - 2019)
Kala Bio's (KALA) quarterly Raw Materials came in at $706000.0 in Q2 2019, up 43.79% quarter-over-quarter from $491000.0 in Q1 2019.
Analysis
Kala Bio (KALA) Raw Materials (2018 - 2019) Analysis & Trends
Kala Bio has disclosed Raw Materials across 2 years of filings, most recently posting $706000.0 for Q2 2019.
- In Q2 2019, Raw Materials changed N/A year-over-year to $706000.0; the TTM figure through Jun 2019 stood at $706000.0 (changed N/A YoY), while the FY2018 annual figure was $350000.0, changed N/A from the prior year.
- Raw Materials came in at $706000.0 for Q2 2019 at Kala Bio, up from $491000.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $706000.0 in Q2 2019 to a low of $350000.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.60 Bn | 192.61 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.45 Bn | 176.27 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.43 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.58 Bn | 73.59 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.66 Bn | 55.48 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.63 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.39 Bn | 30.08 Bn | 992.69 Mn |
| 8 | Biogen | 31.86 Bn | 30.58 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.09 Bn | 29.09 Bn | 1.16 Mn |
| 10 | Kala Bio | 8.59 Mn | 8.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 706,000.00 |
| Mar 31, 2019 | 491,000.00 |
| Dec 31, 2018 | 350,000.00 |